Objective: To evaluate the consistency of the quantitative imaging decision support (QIDS) tool and radiomic analysis using 594 metrics in lung carcinoma on chest CT scan.
Materials And Methods: We included, retrospectively, 150 patients with histologically confirmed lung cancer who underwent chemotherapy and baseline and follow-ups CT scans. Using the QIDS platform, 3 radiologists segmented each lesion and automatically collected the longest diameter and the density mean value. Inter-observer variability, Bland Altman analysis and Spearman's correlation coefficient were performed. QIDS tool consistency was assessed in terms of agreement rate in the treatment response classification. Kruskal Wallis test and the least absolute shrinkage and selection operator (LASSO) method with 10-fold cross validation were used to identify radiomic metrics correlated with lesion size change.
Results: Good and significant correlation was obtained between the measurements of largest diameter and of density among the QIDS tool and the radiologists measurements. Inter-observer variability values were over 0.85. HealthMyne QIDS tool quantitative volumetric delineation was consistent and matched with each radiologist measurement considering the RECIST classification (80-84%) while a lower concordance among QIDS and the radiologists CHOI classification was observed (58-63%). Among 594 extracted metrics, significant and robust predictors of RECIST response were energy, histogram entropy and uniformity, Kurtosis, coronal long axis, longest planar diameter, surface, Neighborhood Grey-Level Different Matrix (NGLDM) dependence nonuniformity and low dependence emphasis as Volume, entropy of Log(2.5 mm), wavelet energy, deviation and root man squared.
Conclusion: In conclusion, we demonstrated that HealthMyne quantitative volumetric delineation was consistent and that several radiomic metrics extracted by QIDS were significant and robust predictors of RECIST response.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482708 | PMC |
http://dx.doi.org/10.1177/1073274820985786 | DOI Listing |
Can J Psychiatry
July 2024
Department of Psychiatry, University of British Columbia, Vancouver, Canada.
Background: e-Health tools using validated questionnaires to assess outcomes may facilitate measurement-based care for psychiatric disorders. MoodFX was created as a free online symptom tracker to support patients for outcome measurement in their depression treatment. We conducted a pilot randomized evaluation to examine its usability, and clinical utility.
View Article and Find Full Text PDFJMIR Ment Health
February 2024
Centre for Neuroscience Studies, Queen's University, Kingston, ON, Canada.
Background: Depression is a hidden burden, yet it is a leading cause of disability worldwide. Despite the adverse effects of depression, fewer than one-third of patients receive care. Internet-based cognitive behavioral therapy (i-CBT) is an effective treatment for depression, and combining i-CBT with supervised care could make the therapy scalable and effective.
View Article and Find Full Text PDFNeuropsychiatr Dis Treat
May 2023
Department of Psychiatry and Clinical Sciences, Duke-National University of Singapore, Singapore, Singapore.
Objective: The current study aimed to evaluate the psychometric features of the Quick Inventory of Depressive Symptomatology, Adolescent version (QIDS-A) and the clinician-rated Children's Depression Rating Scale-Revised (CDRS-R).
Methods: Altogether, 103 outpatients (8 to 17 years) completed the self-report QIDS-A-SR. Clinician interviews of adolescents (QIDS-A-C (Adolescent)) and of parents (QIDS-A-C (Parent)) were combined to create the QIDS-A-C(Composite) and the CDRS-R.
J Affect Disord
March 2023
Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, United States of America. Electronic address:
Objectives: Evaluate whether early improvement in irritability predicts improvement in depression severity in a naturalistic sample of adolescents undergoing pharmacologic treatment for major depressive disorder.
Methods: Adolescents (N = 161) aged 13-18 years with a moderate to severe depressive episode were enrolled. Outcome measures included the Children's Depression Rating Scale-Revised (CDRS-R), Quick Inventory of Depressive Symptomatology (QIDS-A), and Clinical Global Impression scale (CGI).
BJPsych Open
July 2021
Department of Psychological Medicine, Centre for Affective Disorders, Institute of Psychiatry, Psychology & Neuroscience, King's College London, UK; and National Service for Affective Disorders, South London and Maudsley NHS Foundation Trust, UK.
Background: The Patient Health Questionnaire-9 (PHQ-9) is a widely used measure of depression in primary care. It was, however, originally designed as a diagnostic screening tool, and not for measuring change in response to antidepressant treatment. Although the Quick Inventory of Depressive Symptomology (QIDS-SR-16) has been extensively validated for outcome measurement, it is poorly adopted in UK primary care, and, although free for clinicians, has licensing restrictions for healthcare organisation use.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!